Abstract
Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak was declared a pandemic, the magnitude of coronavirus disease 2019 (COVID-19) has continued to grow, putting an unprecedented strain on all medical fields. Its effects on cytopathology workloads have been dramatic. Indeed, despite the implementation of several laboratory biosafety recommendations, cytological screening activities and cytological sampling of patients at low risk of malignancy have been postponed to limit the risk of contagion and to lessen the strain on overwhelmed hospital facilities. In this scenario, a drastic reduction in the total number of cytological specimens has been observed worldwide. This review summarizes the current evidence of the impact of the COVID-19 pandemic on cytopathology practice by focusing on its impact on cytological sample workload.
Reference28 articles.
1. Coronavirus Disease (COVID-19) Situation Reportshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2. Cytopathology Laboratory Considerations during the COVID-19 Pandemic: College of American Pathologists Cytopathology Committeehttps://www.cap.org/laboratory-improvement/news-and-updates/cytopathology-laboratory-considerations-during-the-covid-19-pandemic
3. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献